Basic Biology of the Cardiovascular System¶
Chapter 244 | Part 6: Disorders of the Cardiovascular System
KEY CLINICAL POINTS¶
- The cardiovascular system develops from embryonic mesoderm, with the heart forming as a linear heart tube through processes of looping and chamber specification.
- Endothelial cells regulate vascular tone, hemostasis, and inflammation, while vascular smooth muscle cells control vasoconstriction and contraction via calcium signaling.
- Cardiac contraction is driven by the interplay of sarcomeric proteins (actin, myosin, troponin) and calcium-dependent cross-bridge cycling, modulated by autonomic and metabolic factors.
1. DEFINITION & OVERVIEW¶
The cardiovascular system comprises the heart, blood vessels, and blood, functioning to transport oxygen, nutrients, and hormones while maintaining homeostasis. Development begins in embryogenesis with the formation of the heart tube, which undergoes morphogenesis to form chambers and valves. The system is regulated by endothelial and smooth muscle cells, with critical roles in vascular tone, hemostasis, and cardiac contractility.
1.1 Embryonic Development¶
The heart forms from bilateral heart fields that fuse into a linear heart tube. The first heart field forms the atria, while the second heart field contributes to the ventricles and outflow tract. Neural crest cells and mesodermal derivatives shape the great vessels and valves.
1.2 Vascular Development¶
Blood vessels arise from endothelial progenitors and mesodermal cells. Arteries develop from the aortic arches, while veins form from the cardinal veins. The coronary arteries originate from the proepicardial organ, with neural crest cells critical for remodeling.
2. EPIDEMIOLOGY¶
Cardiovascular diseases (CVD) are leading causes of mortality globally, with risk factors including hypertension, hyperlipidemia, diabetes, and smoking. The prevalence of congenital heart defects is ~0.8%, while atherosclerosis affects ~10% of adults. Age, gender, and genetic predisposition significantly influence disease burden.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Cardiovascular pathologies arise from genetic, environmental, and metabolic factors. Atherosclerosis is driven by endothelial dysfunction, oxidative stress, and lipid accumulation. Hypertension results from vascular remodeling and altered autonomic regulation. Congenital defects stem from developmental disruptions in heart tube formation.
3.1 Endothelial Dysfunction¶
Impaired nitric oxide (NO) production and increased reactive oxygen species (ROS) disrupt vascular homeostasis, promoting inflammation and atherosclerosis.
3.2 Smooth Muscle Cell Proliferation¶
Pathologic smooth muscle cell migration and proliferation contribute to atherosclerosis, hypertension, and vascular stenosis.
4. CLINICAL FEATURES¶
Clinical manifestations include chest pain (angina), dyspnea, syncope, and peripheral edema. Congenital defects may present with cyanosis or heart murmurs. Atherosclerosis leads to ischemia, while hypertension causes left ventricular hypertrophy and renal dysfunction.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses for chest pain include myocardial infarction, pericarditis, and pulmonary embolism. For heart murmurs, conditions like valvular disease, hypertrophic cardiomyopathy, and congenital defects must be considered.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic tools include echocardiography, coronary angiography, and blood tests (e.g., troponin, lipid panel). The Framingham Risk Score and ACC/AHA guidelines aid in CAD risk stratification. Electrocardiography (ECG) detects arrhythmias and ischemia.
Table 244-1: Endothelial Functions in Health and Disease¶
| HOMEOSTATIC PROPERTIES | DYSFUNCTIONAL PROPERTIES |
|---|---|
| Optimize balance between vasodilation and vasoconstriction | Impaired dilation, vasoconstriction |
| Antithrombotic, profibrinolytic | Prothrombotic, antifibrinolytic |
| Anti-inflammatory | Proinflammatory |
| Antiproliferative | Proproliferative |
| Antioxidant | Prooxidant |
| Selective permeability | Impaired barrier function |
Table 244-2: Determinants of Stroke Volume¶
| I. Ventricular Preload | II. Ventricular Afterload | III. Myocardial Contractility |
|---|---|---|
| A. Blood volume | A. Systemic vascular resistance | A. Intramyocardial [Ca2+] ›fl |
| B. Distribution of blood volume | B. Elasticity of arterial tree | B. Cardiac adrenergic nerve activity ›flb |
| 1. Body position | C. Arterial blood volume | C. Circulating catecholamines ›flb |
| I. Ventricular Preload | II. Ventricular Afterload | III. Myocardial Contractility |
|---|---|---|
| 2. Intrathoracic pressure | D. Ventricular wall tension | D. Cardiac rate ›flb |
| 3. Intrapericardial pressure | 1. Ventricular radius | E. Exogenous inotropic agents › |
| 4. Venous tone | 2. Ventricular wall thickness | F. Myocardial ischemia fl |
| 5. Pumping action of skeletal muscles | G. Myocardial cell death (necrosis, apoptosis, autophagy) fl | |
| C. Atrial contraction | H. Alterations of sarcomeric and cytoskeletal proteins fl |
7. MANAGEMENT & TREATMENT¶
Management includes lifestyle modifications (diet, exercise), pharmacologic agents (ACE inhibitors, statins), and revascularization (PCI, CABG). For congenital defects, surgical repair or catheter-based interventions may be required. Monitoring of cardiac function via echocardiography and biomarkers is essential.
8. PROGNOSIS & COMPLICATIONS¶
Prognosis varies by condition; CAD mortality is ~5% within 1 year of MI. Complications include heart failure, arrhythmias, and thromboembolism. Early intervention improves outcomes, while uncontrolled hypertension or diabetes worsens prognosis.
9. SPECIAL CONSIDERATIONS¶
Pregnancy requires monitoring for hypertension and cardiac strain. Pediatric patients may present with congenital anomalies, while elderly patients face increased risks of atherosclerosis and frailty. Genetic counseling is vital for inherited cardiomyopathies.
10. KEY POINTS & CLINICAL PEARLS¶
- Endothelial and smooth muscle dysfunction underlie most cardiovascular diseases. 2. Cardiac contractility is regulated by calcium signaling and autonomic inputs. 3. Early detection and management of risk factors (hypertension, hyperlipidemia) prevent CVD progression.